On the malignant potential of thiopurine therapy.
de Boer
Nanne K H
NK
van Asseldonk
Dirk P
DP
van Bodegraven
Adriaan A
AA
D000284:Administration, Oral; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D003131:Combined Modality Therapy; D016371:Cranial Irradiation; D006801:Humans; D007041:Hypoxanthine Phosphoribosyltransferase / Q000235:genetics; D007124:Immunoenzyme Techniques; D007621:Karyotyping; D015122:Mercaptopurine / Q000008:administration & dosage / Q000009:adverse effects; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D008780:Methyltransferases / Q000378:metabolism; D009154:Mutation / Q000187:drug effects; D016609:Neoplasms, Second Primary / Q000139:chemically induced* / Q000175:diagnosis / Q000378:metabolism; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D011379:Prognosis; D012074:Remission Induction; D012307:Risk Factors; D033581:Stem Cell Transplantation; D015996:Survival Rate; D016896:Treatment Outcome
D015122:Mercaptopurine; D008780:Methyltransferases; C022745:thiopurine methyltransferase; D007041:Hypoxanthine Phosphoribosyltransferase; D008727:Methotrexate